Your Health, We Care
Another NameLuciSoVe,索达,吉三代
IndicationsIt is indicated for the treatment of adult and pediatric patients aged 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection. This includes patients without cir
Reg No.10 L 1226/24
Inspection NO.2564-24
Sofosbuvir/Velpatasvir (Sofosbuvir/Velpatasvir, commonly known as "Sofosbuvir/Velpatasvir Combination Tablets") produced by Lucius Pharmaceuticals is a pan-genotypic hepatitis C treatment drug. It features high cure rate, relatively fixed treatment course and good overall tolerability, providing patients with a convenient and effective treatment option.
Overview of Key Usage Information for Sofosbuvir/Velpatasvir.
This product is a fixed-dose combination preparation, with the main active ingredients being sofosbuvir and velpatasvir.
It is indicated for patients aged 3 years and older with chronic hepatitis C (HCV) infection.
Adults: Take 1 tablet orally once daily.
Pediatric patients: Select tablets or oral granules of the corresponding strength based on body weight.
Elderly patients and patients with mild to moderate hepatic or renal impairment: Generally, no dosage adjustment is required.
Pregnant and lactating women: The use of this drug requires careful evaluation by a healthcare provider.
In case of overdosage, seek medical attention immediately and receive symptomatic and supportive treatment.
Store the drug in a sealed container at a temperature below 30°C.
Sofosbuvir and velpatasvir are well absorbed after oral administration, with clear in vivo metabolic pathways. Attention should be paid to potential drug-drug interactions.
FDA，2022.04
